Abstract
Introduction Rapid qualitative antigen testing has been widely used for the laboratory diagnosis of COVID-19 with nasopharyngeal samples. Saliva samples have been used as alternative samples, but the analytical performance of those samples for qualitative antigen testing has not been sufficiently evaluated.
Methods A prospective observational study evaluated the analytical performance of three In Vitro Diagnostics (IVD) approved COVID-19 rapid antigen detection kits for saliva between June 2022 and July 2022 in Japan using real-time reverse transcription polymerase chain reaction (RT-PCR) as a reference. A nasopharyngeal sample and a saliva sample were simultaneously obtained, and RT-PCR was performed.
Results In total, saliva samples and nasopharyngeal samples were collected from 471 participants (140 RT-PCR-positive saliva samples and 143 RT-PCR-positive nasopharyngeal samples) for the analysis. The median Ct values were 25.5 (interquartile range [IQR]: 21.9-28.8) for saliva samples and 17.1 (IQR: 15.5-18.7) for nasopharyngeal samples (p<0.001). Compared with saliva samples of RT-PCR, the sensitivity and specificity were 46.4% and 99.7% for ImunoAce SARS-CoV-2 Saliva, 59.3% and 99.1% for Espline SARS-CoV-2 N, and 61.4% and 98.8% for QuickChaser Auto SARS-CoV-2, respectively. The sensitivity is >90% for saliva samples with a moderate-to-high viral load (Ct<25), whereas the sensitivity is <70% for high-viral-load nasopharyngeal samples (Ct<20).
Conclusion COVID-19 rapid antigen detection kits with saliva showed high specificities, but the sensitivities varied among kits, and the analytical performance of saliva qualitative antigen detection kits was much worse than that of kits using nasopharyngeal samples.
Competing Interest Statement
FUJIREBIO, Inc., and MIZUHO MEDY Co., Ltd., provided funds for research expenses and antigen kits without charge. Hiromichi Suzuki received advisory fees from MIZUHO MEDY Co., Ltd. The other authors have no conflicts of interest.
Funding Statement
FUJIREBIO, Inc., and MIZUHO MEDY Co., Ltd., provided funds for research expenses and antigen kits without charge. Hiromichi Suzuki received advisory fees from MIZUHO MEDY Co., Ltd. The other authors have no conflicts of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics board of Tsukuba Medical Center Hospital (approval number:2021-055) approved the protocol.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of each author: Norihiko Terada, terada.norihiko.ck{at}ms.hosp.tsukuba.ac.jp; Yusaku Akashi, yusaku-akashi{at}umin.ac.jp; Yuto Takeuchi, yuto-takeuchi{at}umin.ac.jp; Atsuo Ueda, atsuo.ueda06090727{at}outlook.jp; Shigeyuki Notake, notake{at}tmch.or.jp; Koji Nakamura, koji-nakamura{at}tmch.or.jp; Hiromichi Suzuki, hsuzuki{at}md.tsukuba.ac.jp
Data Availability
All data produced in the present work are contained in the manuscript
